CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


SARS-CoV-2 vaccine (inactivated)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D007239 Infection NIH 0.05

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia

This phase III trial aims to assess the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (inactivated) and lot-to-lot consistency evaluation

NCT04508075 SARS-CoV2 Infection Biological: SARS-CoV-2 vaccine (inactivated) Biological: Placebo
MeSH:Infection

Primary Outcomes

Description: Percentage of laboratory-confirmed COVID-19 cases

Measure: Incidence of laboratory-confirmed COVID-19 after the second dose

Time: 14 days to 6 months after the second dose

Secondary Outcomes

Description: Percentage of suspected COVID-19 cases

Measure: Incidence of suspected COVID-19 cases

Time: within 14 days to 6 months after the second dose.

Description: Percentage of laboratory-confirmed cases (severe, critical, death)

Measure: Incidence of laboratory-confirmed cases (severe, critical and death)

Time: within 14 days to 6 months after the second dose

Description: Percentage of subjects with four-fold increasing anti-S antibody IgG titer (ELISA) compare to baseline and between batches

Measure: Seroconversion rate anti-S antibody IgG titer (ELISA)

Time: 14 days after two doses of vaccination

Description: Percentage of subjects with four-fold increasing anti-S antibody IgG titer (ELISA) compare to baseline and between batches

Measure: Seroconversion rate anti-S antibody IgG titer (ELISA)

Time: 6 months after two doses of vaccination

Description: Percentage of subjects with four-fold increasing serum neutralizing antibody compared to baseline and between batches

Measure: Seropositive rate of neutralizing antibodies

Time: 14 days after two doses of vaccination

Description: Percentage of subjects with four-fold increasing serum neutralizing antibody compared to baseline and between batches

Measure: Seropositive rate of neutralizing antibodies

Time: 6 months after two doses of vaccination

Other Outcomes

Description: Number of Local reactions and systemic events

Measure: Local reaction and systemic events

Time: 30 minutes to 14 days after each vaccination

Description: Number of Local reactions and systemic events

Measure: Local reaction and systemic events occurring after the last vaccination

Time: 14 days to 28 days following last vaccination

Description: Number of any SAE occur

Measure: Serious adverse events during study

Time: 6 months after the last dose


No related HPO nodes (Using clinical trials)